Can ferric citrate lead to iron overload in peritoneal dialysis patients?

Nabeel Aslam, Maulik Govani, Luke M. Basdeo, Hani M. Wadei

Research output: Contribution to journalArticlepeer-review

Abstract

Ferric citrate (FC), a novel oral phosphate binder, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients receiving dialysis. FC binds to dietary phosphate in the gastrointestinal (GI) tract producing ferric phosphate that is excreted in feces. However, a small quantity of iron is systemically absorbed. There are limited data regarding the safety of the maximum approved dose of FC among peritoneal dialysis (PD) patients. We present a series of 3 PD patients who developed iron overload while receiving FC for management of hyperphosphatemia. These cases highlight the importance of close monitoring of iron studies and question whether a lower maximum dose of FC should be recommended in PD patients. Further studies are needed to assess the safety of the maximum approved dose of FC among PD patients.

Original languageEnglish (US)
Pages (from-to)262-266
Number of pages5
JournalClinical nephrology
Volume93
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • Ferric citrate
  • Hyperphosphatemia
  • Iron overload
  • Peritoneal dialysis
  • Phosphate binders

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Can ferric citrate lead to iron overload in peritoneal dialysis patients?'. Together they form a unique fingerprint.

Cite this